go-v.orgdoi

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development

JS Berry, Timothy J. Vreeland, D. K. Hale, DO Jackson, AF Trappey, J.M. Greene, MO Hardin, Garth S. Herbert, Guy Travis Clifton, GE Peoples · Journal of Cancer · 2017

  • DOI 10.7150/jca.16450
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2017

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2017

Abstract

INTRODUCTION: Peptide vaccines offer anti-tumor efficacy with very low toxicity. However, repeat stimulation with an immunogenic peptide leads to activation induced cell death (AICD), decreasing efficacy. We engineered variants of an immunogenic peptide (E39) and tested their ability to induce a robust, sustainable immune response. METHODS: Multiple variants of E39 were created by exchanging 1 or 2 amino acids. We tested the PBMC proliferation, cytokine production and cytolytic activity induced by each variant peptide. RESULTS: AICD, while stimulation with E39' led to T-cell proliferation with less evidence of AICD, modest cytokine production and high CTL activity.

CONCLUSIONS: E39' appears to be the optimal variant of E39 for inducing effective long-term immunity.

Open the resolved locator · 10.7150/jca.16450

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:47 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v08p1255.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.